Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
17.52
+0.22 (1.27%)
At close: May 12, 2025, 4:00 PM
17.33
-0.19 (-1.08%)
After-hours: May 12, 2025, 7:35 PM EDT
Apellis Pharmaceuticals Employees
As of December 31, 2024, Apellis Pharmaceuticals had 710 total employees, including 705 full-time and 5 part-time employees. The number of employees increased by 4 or 0.57% compared to the previous year.
Employees
710
Change (1Y)
4
Growth (1Y)
0.57%
Revenue / Employee
$1,092,731
Profits / Employee
-$315,042
Market Cap
2.20B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
APLS News
- 5 days ago - Apellis Pharmaceuticals, Inc. (APLS) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 6 days ago - Apellis Pharmaceuticals to Present at Upcoming Investor Conferences - GlobeNewsWire
- 12 days ago - Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results - GlobeNewsWire
- 21 days ago - Apellis Announces Craig Wheeler to Join the Board of Directors - GlobeNewsWire
- 5 weeks ago - FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals - Benzinga
- 5 weeks ago - Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN - GlobeNewsWire
- 2 months ago - Apellis Pharmaceuticals: A Mixed Bag - Seeking Alpha